In a patient with mild hyponatremia (serum sodium 132 mmol/L) and hypochloremia who is taking lisinopril‑hydrochlorothiazide, should routine sodium supplementation be prescribed?

No, Do Not Give Sodium Supplements

In this patient with mild thiazide-induced hyponatremia (sodium 132 mmol/L), sodium supplementation is contraindicated and potentially harmful—the appropriate management is to reassess the HCTZ component of the lisinopril-HCTZ regimen and monitor closely.

Why Sodium Supplements Are Wrong

Thiazide-induced hyponatremia occurs because these diuretics impair the kidney's ability to excrete free water while simultaneously causing inappropriate urinary sodium losses 1. Adding oral sodium supplements would paradoxically worsen the problem because:

• The kidneys will simply excrete the supplemented sodium in the urine (as evidenced by the typical high urinary sodium concentration of 64 mmol/L in thiazide-induced hyponatremia 2)
• This creates more osmotically-obligated water retention
• The net effect is further dilution of serum sodium

The Correct Management Approach

Immediate Actions (Next 1-2 Weeks)

1. Reduce or discontinue the HCTZ component 1

   • Your patient is on lisinopril-HCTZ 20/12.5 mg
   • Consider switching to lisinopril monotherapy 20 mg
   • The ACE inhibitor alone provides adequate blood pressure control in most patients
   • This addresses the root cause rather than fighting against the medication

2. Assess volume status and symptoms carefully

   • Thiazide-induced hyponatremia typically presents with euvolemia or mild hypovolemia
   • Your patient shows no signs of volume overload (no mention of edema, heart failure)
   • Most patients are asymptomatic with sodium 132 mmol/L 3

3. Implement fluid restriction if needed

   • For asymptomatic mild hyponatremia: initial restriction of 500 mL/day adjusted to sodium levels 4
   • However, in thiazide-induced cases, stopping the offending agent is more effective than fluid restriction alone

Monitoring Protocol

Repeat BMP in 1-2 weeks as already planned to ensure:

• Sodium is rising (not declining further)
• Renal function remains stable (current eGFR 59)
• Potassium remains normal (currently 4.1)

Key Clinical Context

This patient's hyponatremia developed while on HCTZ, with sodium dropping from 136-143 to 132 mmol/L. The timing and pattern are classic for thiazide-induced hyponatremia, which:

• Occurs in 79% women, mean age 75 years 2—your patient fits this profile
• Typically presents within 19 days of starting treatment but can occur anytime 2
• Is the leading cause of drug-induced hyponatremia requiring hospital admission 2

Critical Pitfalls to Avoid

1. Do not add sodium supplements—this is physiologically counterproductive in thiazide-induced hyponatremia

2. Do not ignore mild hyponatremia—even mild chronic hyponatremia (sodium 130-135) increases fall risk, fractures, and cognitive impairment 3

3. Do not continue HCTZ unchanged—thiazide-induced hyponatremia rarely resolves without medication adjustment 2, 5

4. Do not correct too rapidly if sodium drops further—if the patient becomes symptomatic or sodium falls below 125 mmol/L, correction should not exceed 10 mEq/L in 24 hours to avoid osmotic demyelination 3

Alternative Antihypertensive Strategy

If blood pressure control becomes inadequate on lisinopril monotherapy:

• Add a calcium channel blocker (amlodipine)
• Consider a low-dose ARB instead of restarting thiazide
• Avoid reintroducing any thiazide diuretic given this patient's demonstrated susceptibility 2, 6

The evidence is clear: thiazide-induced hyponatremia requires removal of the causative agent, not supplementation to overcome it 1, 2.